ArticleJournal of experimental & clinical cancer research : CR2018

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.

Linglong Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.